Both were approved by the FDA for the treatment of ATTRv-associated neuropathy in 2018 after two randomized controlled trials (RCTs) demonstrated benefit in reducing circulating levels of TTR and neuropathy impairment and improving quality of life compared to placebo [11, 12]. This evidence concerns the gene TTR and neuropathy.